Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Apr 18, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This study investigated the effectiveness and safety of inotuzumab ozogamicin (Besponsa; INO) in patients with relapsed/refractory (r/r) acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The data showed that the treatment had good effectiveness and manageable side effects for these patients.

Some background

A high number of patients with acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL) experience relapse (worsening of the disease) or are refractory (not responsive) to standard treatments.

Inotuzumab ozogamicin (INO) is an immunotherapy already approved for the treatment of relapsed/refractory (r/r) ALL. However, there are few studies focusing on the effectiveness and safety of INO in patients with r/r ALL and r/r NHL.

Methods & findings

This study investigated 12 studies on INO in patients with r/r ALL and NHL. It involved 644 patients overall. They were divided into two groups. 471 patients had r/r ALL and 173 patients had r/r NHL.

The overall complete remission (CR; no signs of cancer) rate was 67% for patients with ALL. 45% of patients with ALL had a minimum residual disease (MRD; a small number of cancer cells left after treatment) response. 

In patients with NHL the CR rate was 28%. 

The most common side effects were low platelet (blood cells involved in clotting) counts (48%) and low white blood cell counts (29%).

The bottom line

This study concluded that INO was effective for the treatment of r/r ALL and NHL with manageable side effects. 

The fine print

The number of studies included in the analysis was very low. The dose of INO was different in a couple of studies.

Published By :

Clinical lymphoma, myeloma & leukemia

Date :

Mar 01, 2021

Original Title :

Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.

click here to get personalized updates